AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
15,817,600
15,787,400
15,940,700
14,570,600
Cost of Revenue
2,379,100
2,191,400
2,168,000
1,860,800
Gross Profit
13,438,500
13,596,000
13,772,700
12,709,800
Operating Expenses
Research Development
2,037,600
2,266,200
2,100,100
2,575,700
Selling General and Administrative
5,497,500
4,521,800
5,016,700
4,740,300
Total Operating Expenses
13,443,300
13,340,300
14,313,900
13,786,400
Operating Income or Loss
-4,800
255,700
-541,200
-1,076,600
Interest Expense
801,300
911,200
1,095,600
1,295,600
Total Other Income/Expenses Net
-9,546,300
-6,246,600
-8,817,300
-529,700
Income Before Tax
-10,289,300
-6,856,900
-10,386,400
-2,832,000
Income Tax Expense
-1,045,600
-1,770,700
-6,670,400
-1,897,000
Income from Continuing Operations
-9,243,700
-5,086,200
-3,716,000
-935,000
Net Income
-9,253,700
-5,096,400
-4,125,500
14,973,400
Net Income available to common shareholders
-9,253,700
-5,142,800
-4,403,900
14,695,000
Reported EPS
Basic
-
-15.26
-13.19
38.18
Diluted
-
-15.26
-13.19
38.18
Weighted average shares outstanding
Basic
-
337,000
333,800
384,900
Diluted
-
337,000
333,800
384,900
EBITDA
-
802,900
-1,922,200
4,934,000